"Chemokine CCL5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CC-type chemokine that is a chemoattractant for EOSINOPHILS; MONOCYTES; and LYMPHOCYTES. It is a potent and selective eosinophil chemotaxin that is stored in and released from PLATELETS and activated T-LYMPHOCYTES. Chemokine CCL5 is specific for CCR1 RECEPTORS; CCR3 RECEPTORS; and CCR5 RECEPTORS. The acronym RANTES refers to Regulated on Activation, Normal T Expressed and Secreted.
| Descriptor ID |
D018946
|
| MeSH Number(s) |
D12.644.276.374.200.110.250 D12.776.467.374.200.110.250 D23.125.300.110.250 D23.469.200.110.250 D23.529.374.200.110.250
|
| Concept/Terms |
Chemokine CCL5- Chemokine CCL5
- CCL5, Chemokine
- RANTES Protein, T-Cell
- RANTES Protein, T Cell
- T-Cell RANTES Protein
- CCL5 Chemokine
- Chemokine, CCL5
- RANTES
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CCL5".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CCL5".
This graph shows the total number of publications written about "Chemokine CCL5" by people in this website by year, and whether "Chemokine CCL5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CCL5" by people in Profiles.
-
Deficiency in lymphotoxin ? receptor protects from atherosclerosis in apoE-deficient mice. Circ Res. 2015 Apr 10; 116(8):e57-68.
-
RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies. PLoS One. 2011; 6(12):e25734.
-
In situ profiling of adipokines in subcutaneous microdialysates from lean and obese individuals. Am J Physiol Endocrinol Metab. 2008 Nov; 295(5):E1095-105.
-
RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Eur J Endocrinol. 2008 May; 158(5):R1-5.
-
Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes. 2006 Aug; 55(8):2340-6.
-
Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes. 2005 Dec; 54 Suppl 2:S11-7.
-
Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol. 2006 Jan; 26(1):194-9.
MeSH information
